2025
Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women
Nuckols V, Shoemaker L, Kuczmarski A, Haigh K, McGinty S, Del Vecchio A, Schwab A, Edwards D, Taylor H, Wenner M. Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women. AJP Heart And Circulatory Physiology 2025, 328: h327-h332. PMID: 39773019, PMCID: PMC12175985, DOI: 10.1152/ajpheart.00815.2024.Peer-Reviewed Original ResearchConceptsPostmenopausal womenExogenous estradiol administrationEndothelin B receptorEstradiol administrationPremenopausal womenLactated RingeHealthy postmenopausal womenYoung womenLaser Doppler flowmetryEndothelin-BVasodilatory responseTransdermal patchDoppler flowmetryCutaneous microcirculationVasodilationEstradiolAdministrationWomenReceptorsRingerBlockadeFlowmetry
2023
Examining the association between urinary triclosan levels and menopausal status: results from the National Health and Nutrition Examination Survey, 2003 to 2016
Beroukhim G, Kayani J, Taylor H, Pal L. Examining the association between urinary triclosan levels and menopausal status: results from the National Health and Nutrition Examination Survey, 2003 to 2016. Menopause The Journal Of The North American Menopause Society 2023, 30: 906-912. PMID: 37625087, DOI: 10.1097/gme.0000000000002233.Peer-Reviewed Original ResearchConceptsMenopausal statusBody mass indexSmoking exposureMass indexNational HealthLinear regression analysisTCS levelsTriclosan levelsRetrospective cross-sectional studyMultivariable linear regression analysisReproductive health questionnaireUrinary triclosan levelsDuration of menopauseMultivariate linear regression analysisNutrition Examination SurveyCross-sectional studyYears of ageRegression analysisFemale participantsPostmenopausal statusPostmenopausal womenPremenopausal womenSurgical menopausePremature menopauseUrinary levelsAssessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women
Siblini H, Al-Hendy A, Segars J, González F, Taylor H, Singh B, Flaminia A, Flores V, Christman G, Huang H, Johnson J, Zhang H. Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women. Nutrients 2023, 15: 320. PMID: 36678191, PMCID: PMC9861948, DOI: 10.3390/nu15020320.Peer-Reviewed Original ResearchConceptsReproductive-aged womenLiver function testsUterine fibroidsUnexplained infertilityClomiphene citrateSerum liver function testsEpigallocatechin gallateSigns of drugSerum folate levelsGreen tea catechinsHepatic safetyPremenopausal womenProspective cohortDaily doseLiver injuryFunction testsTreatment armsLiver toxicityClinical studiesCommon causeFolate levelsEarly safety assessmentInterim analysisNormal rangeUse of EGCG
2020
Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis
Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. Fertility And Sterility 2020, 115: 423-430. PMID: 33066973, DOI: 10.1016/j.fertnstert.2020.07.013.Peer-Reviewed Original ResearchConceptsSevere endometriosis-associated painEndometriosis-associated painNumerical rating scaleNonmenstrual pelvic painPelvic painWorst painMonth 3Rating ScalePain numerical rating scaleMeaningful changePremenopausal womenSevere endometriosisGlobal ImpressionClinical trialsMAIN OUTCOMEPainDysmenorrheaPhase IIIWomenElagolixResponsivenessTrialsPlaceboEndometriosisPatients
2019
Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain
Leyland N, Taylor H, Archer D, Peloso P, Soliman A, Palac H, Martinez M, Abrao M. Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain. Journal Of Endometriosis And Pelvic Pain Disorders 2019, 11: 171-180. DOI: 10.1177/2284026519872401.Peer-Reviewed Original ResearchEndometriosis-associated painElagolix dosesSevere dyspareuniaRescue analgesic agentsPhase 3 studyHealth-related qualityDaily electronic diarySubgroup of womenDose-dependent mannerDyspareunia scoresElagolix treatmentPremenopausal womenBID groupAnalgesic agentsActive womenDyspareuniaPainResponse rateMore monthsPlaceboMeaningful decreaseElagolixSexual relationshipsElectronic diaryModule scoresImpact of Elagolix on Quality of Life Among Endometriosis Patients: A Pooled Analysis of 2 Phase III Clinical Trials [13J]
Taylor H, Soliman A, Palac H, Surrey E. Impact of Elagolix on Quality of Life Among Endometriosis Patients: A Pooled Analysis of 2 Phase III Clinical Trials [13J]. Obstetrics And Gynecology 2019, 133: 110-110. DOI: 10.1097/01.aog.0000558829.95268.69.Peer-Reviewed Original ResearchSevere painMonth 3Scale scoreGonadotrophin-releasing hormone antagonistSevere endometriosis-associated painPhase III clinical trialsEndometriosis Health ProfileEndometriosis-associated painPhase III randomizedPlacebo-controlled trialEndometriosis-associated symptomsHealth-related qualityDose-dependent fashionQuality of lifePremenopausal womenHRQL questionnairesMonth 6EHP-30Endometriosis patientsPooled analysisClinical trialsMonths 1Health profileBaseline scoresElagolixEffects of bazedoxifene/conjugated estrogens on reproductive endocrinology and reproductive tract ultrasonographic appearance in premenopausal women: a preliminary study
Flores VA, Leone C, Taylor HS, Stachenfeld NS. Effects of bazedoxifene/conjugated estrogens on reproductive endocrinology and reproductive tract ultrasonographic appearance in premenopausal women: a preliminary study. Gynecological Endocrinology 2019, 35: 390-394. PMID: 30668182, DOI: 10.1080/09513590.2018.1559288.Peer-Reviewed Original ResearchConceptsBZA/CEPremenopausal womenConjugated estrogensReproductive hormonesUltrasonographic appearanceBazedoxifene/conjugated estrogensAbnormal ovarian folliculogenesisReproductive hormone changesCase series studyUnited States FoodEstrogen-receptor complexEndometrial alterationsDaily administrationSerum assessmentLH surgeMenopausal womenMenopausal symptomsMenstrual cycleClinical trialsEndocrinologic functionsOvarian morphologyHormone levelsPosttreatment valuesMurine modelOvarian folliculogenesis
2018
86 Elagolix Reduced Dyspareunia and Improved Health-Related Quality of Life in Premenopausal Women with Endometriosis-Associated Pain
Leyland N, Taylor H, Archer D, Peloso P, Schwefel B, Soliman A, Martinez M, Abrao M. 86 Elagolix Reduced Dyspareunia and Improved Health-Related Quality of Life in Premenopausal Women with Endometriosis-Associated Pain. Journal Of Minimally Invasive Gynecology 2018, 25: s55-s56. DOI: 10.1016/j.jmig.2018.09.093.Peer-Reviewed Original ResearchElagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain
Leyland N, Taylor H, Archer D, Peloso P, Schwefel B, Soliman A, Martinez M, Abrao M. Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain. Fertility And Sterility 2018, 110: e82-e83. DOI: 10.1016/j.fertnstert.2018.07.249.Peer-Reviewed Original ResearchBazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis
Hill AM, Lessey B, Flores VA, Taylor HS. Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis. Clinical Case Reports 2018, 6: 990-994. PMID: 29881549, PMCID: PMC5986051, DOI: 10.1002/ccr3.1501.Peer-Reviewed Original Research
2009
Diminished vaginal HOXA13 expression in women with pelvic organ prolapse
Connell KA, Guess MK, Tate A, Andikyan V, Bercik R, Taylor HS. Diminished vaginal HOXA13 expression in women with pelvic organ prolapse. Menopause The Journal Of The North American Menopause Society 2009, 16: 529-533. PMID: 19423998, PMCID: PMC2704499, DOI: 10.1097/gme.0b013e31818fb0c2.Peer-Reviewed Original ResearchConceptsPelvic organ prolapsePremenopausal controlsPremenopausal womenOrgan prolapseHOXA13 expressionPOP groupExpression of HOXA13Real-time polymerase chain reactionExtracellular matrix metabolismEstrogen therapyPostmenopausal womenYounger patientsLeuprolide groupSmoking cessationLeuprolide acetatePolymerase chain reactionBiopsy specimensPreventive strategiesGenetic predispositionVaginal expressionProlapseMatrix metabolismWeight lossWomenVagina
2003
Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk
Chu MC, Rath KM, Huie J, Taylor HS. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Human Reproduction 2003, 18: 1570-1573. PMID: 12871864, DOI: 10.1093/humrep/deg330.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseFSH levelsOvarian functionRisk factorsBasal FSHCardiovascular riskDay 3 serum FSH levelsIU/Day 3 FSH levelsElevated basal FSHNormal estradiol levelsCardiac risk factorsCardiovascular risk factorsSerum FSH levelsNormal cycling womenFunctional ovarian reserveHormone replacement therapyLack of estrogenNormal menstrual cycleMajor risk factorCause of deathPremenopausal womenCardiovascular benefitsOvarian reserveSerum FSH
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply